Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS-20 in Patients With Ulcerative Colitis
NCT04908644Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Aug 2021
- Primary completion
- Nov 2024
- Modality
- Complex Communities
- Countries
- 1
01
Overview
Randomised, double-blind trial in ulcerative colitis (UC) comparing MS-20 with Placebo (2 arms). Primary endpoints: Change from baseline structural of gut microbiota at 16 weeks and Change from baseline in the abundance and variability of gut microbiota at 16 weeks. Started Aug 2021; status: recruiting.
02
Drugs
MicrSoy-20
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04908644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908644.